{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:22:46Z","timestamp":1773523366924,"version":"3.50.1"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report on 2 patients with drug-resistant tuberculous meningitis diagnosed and treated in a high-resource, low-incidence setting. Both patients were treated with multidrug regimens including bedaquiline, a nitroimidazole, cycloserine, and linezolid. Drug selection was informed by molecular diagnostics, susceptibility testing, and pharmacokinetic and clinical data. Adverse events included suicidal ideation, cytopenias, ototoxicity, and neuropathy. There was discordance between phenotypic (susceptible) and genotypic (resistant) drug susceptibility testing for rifampin. After treatment, both patients had excellent clinical outcomes, with at least 12 months of post-treatment follow-up.<\/jats:p>\n                  <jats:p>These clinical cases provide an opportunity to explore the role of molecular diagnostics in the diagnosis of drug-resistant tuberculous meningitis, drug regimen selection in the era of novel oral regimens, and clinical decision-making in the setting of discordance between genotypic and phenotypic drug susceptibility testing.<\/jats:p>","DOI":"10.1093\/ofid\/ofag046","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:42:34Z","timestamp":1770122554000},"source":"Crossref","is-referenced-by-count":1,"title":["Drug-Resistant Tuberculous Meningitis (DR-TBM) in a Low-Incidence Setting: Two Cases and an Evidence Review Highlighting Key Advances and Knowledge Gaps in Clinical Management"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0457-0795","authenticated-orcid":false,"given":"Karol F","family":"Boschung","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick H P","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Division of Infectious Diseases, Surrey Memorial Hospital , Surrey, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Werry","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Surrey Memorial Hospital , Surrey, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Sekirov","sequence":"additional","affiliation":[{"name":"BCCDC Public Health Laboratory, BC Centre for Disease Control , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4244-6468","authenticated-orcid":false,"given":"Shannon L","family":"Turvey","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Tuberculosis Services, BC Centre for Disease Control , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria J","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Tuberculosis Services, BC Centre for Disease Control , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8879-4989","authenticated-orcid":false,"given":"James","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Tuberculosis Services, BC Centre for Disease Control , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-152X","authenticated-orcid":false,"given":"William J A","family":"Connors","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Tuberculosis Services, BC Centre for Disease Control , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026022508012338600_ofag046-B1","author":"British Columbia Centre for Disease Control"},{"key":"2026022508012338600_ofag046-B2","author":"World Health Organization"},{"key":"2026022508012338600_ofag046-B3","doi-asserted-by":"crossref","first-page":"ofw150","DOI":"10.1093\/ofid\/ofw150","article-title":"Clinical impact on tuberculosis treatment outcomes of discordance between molecular and growth-based assays for rifampin resistance, California 2003-2013","volume":"3","author":"Shah","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2026022508012338600_ofag046-B4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5588\/ijtld.11.0178","article-title":"Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis","volume":"16","author":"Williamson","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026022508012338600_ofag046-B5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5588\/ijtld.13.0459","article-title":"Diagnostic dilemma: treatment outcomes of tuberculosis patients with inconsistent rifampicin susceptibility","volume":"18","author":"Pang","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026022508012338600_ofag046-B6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jinf.2011.07.005","article-title":"Multidrug resistant tuberculous meningitis in the United States, 1993\u20132005","volume":"63","author":"Vinnard","year":"2011","journal-title":"J Infect"},{"key":"2026022508012338600_ofag046-B7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijmmb.2021.05.013","article-title":"A decade of drug-resistant tuberculous meningitis: a wake-up call for patient-centric therapy","volume":"39","author":"Sharma","year":"2021","journal-title":"Indian J Med Microbiol"},{"key":"2026022508012338600_ofag046-B8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/cid\/cix230","article-title":"Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen","volume":"65","author":"Heemskerk","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026022508012338600_ofag046-B9","first-page":"102230","article-title":"Cerebrospinal fluid AFB smear in adults with tuberculous meningitis: a systematic review and diagnostic test accuracy meta-analysis","volume":"135","author":"Stadelman","year":"2022","journal-title":"Tuberc Edinb Scotl"},{"key":"2026022508012338600_ofag046-B10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.arbres.2022.07.012","article-title":"Rapid diagnosis of XDR and pre-XDR TB: a systematic review of available tools","volume":"58","author":"Saderi","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2026022508012338600_ofag046-B11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1473-3099(19)30649-8","article-title":"Xpert MTB\/RIF ultra versus Xpert MTB\/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study","volume":"20","author":"Donovan","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026022508012338600_ofag046-B12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(17)30474-7","article-title":"Diagnostic accuracy of Xpert MTB\/RIF ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study","volume":"18","author":"Bahr","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026022508012338600_ofag046-B13","first-page":"CD012768","article-title":"Low-complexity automated nucleic acid amplification tests for extrapulmonary tuberculosis and rifampicin resistance in adults and adolescents","volume":"8","author":"Kohli","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022508012338600_ofag046-B14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(19)30550-X","article-title":"Xpert MTB\/RIF ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study","volume":"20","author":"Cresswell","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026022508012338600_ofag046-B15","first-page":"CD014841","article-title":"Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin","volume":"5","author":"Pillay","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022508012338600_ofag046-B16","first-page":"102513","article-title":"Utilization of Truenat chips in defining XDR, pre-XDR and MDR in tuberculous meningitis","volume":"147","author":"Sharma","year":"2024","journal-title":"Tuberc Edinb Scotl"},{"key":"2026022508012338600_ofag046-B17","doi-asserted-by":"crossref","first-page":"e0128723","DOI":"10.1128\/jcm.01287-23","article-title":"Targeted sequencing from cerebrospinal fluid for rapid identification of drug-resistant tuberculous meningitis","volume":"62","author":"Tram","year":"2024","journal-title":"J Clin Microbiol"},{"key":"2026022508012338600_ofag046-B18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1473-3099(24)00586-3","article-title":"Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows","volume":"25","author":"Colman","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026022508012338600_ofag046-B19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jac\/dkz564","article-title":"Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact","volume":"75","author":"Van Rie","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026022508012338600_ofag046-B20","doi-asserted-by":"crossref","first-page":"e0153563","DOI":"10.1371\/journal.pone.0153563","article-title":"Discordance across phenotypic and molecular methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB incidence country","volume":"11","author":"Ahmad","year":"2016","journal-title":"PLoS One"},{"key":"2026022508012338600_ofag046-B21","first-page":"100410","article-title":"Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomes","volume":"34","author":"Bonsa","year":"2024","journal-title":"J Clin Tuberc Mycobact Dis"},{"key":"2026022508012338600_ofag046-B22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.21037\/jtd.2019.01.58","article-title":"Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic L\u00f6wenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients","volume":"11","author":"Kang","year":"2019","journal-title":"J Thorac Dis"},{"key":"2026022508012338600_ofag046-B23","doi-asserted-by":"crossref","first-page":"e01550","DOI":"10.1128\/AAC.01550-17","article-title":"What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi- and extensively drug-resistant tuberculosis","volume":"62","author":"Heyckendorf","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022508012338600_ofag046-B24","first-page":"102004","article-title":"Transmission of Mycobacterium tuberculosis presenting unusually high discordance between genotypic and phenotypic resistance to rifampicin in an endemic tuberculosis setting","volume":"125","author":"Brandao","year":"2020","journal-title":"Tuberc Edinb Scotl"},{"key":"2026022508012338600_ofag046-B25","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/cid\/ciac208","article-title":"Randomized clinical trial of high-dose rifampicin with or without levofloxacin versus standard of care for pediatric tuberculous meningitis: the TBM-KIDS trial","volume":"75","author":"Paradkar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026022508012338600_ofag046-B26","doi-asserted-by":"crossref","first-page":"e088543","DOI":"10.1136\/bmjopen-2024-088543","article-title":"Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis","volume":"15","author":"Huynh","year":"2025","journal-title":"BMJ Open"},{"key":"2026022508012338600_ofag046-B27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13063-024-08133-6","article-title":"Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial)","volume":"25","author":"Inbaraj","year":"2024","journal-title":"Trials"},{"key":"2026022508012338600_ofag046-B28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17512433.2019.1552831","article-title":"Intensified antibiotic treatment of tuberculosis meningitis","volume":"12","author":"Cresswell","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026022508012338600_ofag046-B29","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/acsinfecdis.9b00473","article-title":"Radiosynthesis and biodistribution of 18F-linezolid in Mycobacterium tuberculosis-infected mice using positron emission tomography","volume":"6","author":"Mota","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2026022508012338600_ofag046-B30","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1038\/s41467-022-35730-3","article-title":"Dynamic 18F-pretomanid PET imaging in animal models of TB meningitis and human studies","volume":"13","author":"Mota","year":"2022","journal-title":"Nat Commun"},{"key":"2026022508012338600_ofag046-B31","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2147\/IDR.S401281","article-title":"Pharmacokinetics of antituberculosis drugs in plasma and cerebrospinal fluid in a patient with pre-extensive drug resistant tuberculosis meningitis","volume":"16","author":"Liang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026022508012338600_ofag046-B32","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/cid\/ciab992","article-title":"Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness","volume":"75","author":"Kempker","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026022508012338600_ofag046-B33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/INF.0000000000001114","article-title":"Linezolid is associated with improved early outcomes of childhood tuberculous meningitis","volume":"35","author":"Li","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2026022508012338600_ofag046-B34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1186\/s12879-021-06705-4","article-title":"Decreased mortality seen in rifampicin\/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China","volume":"21","author":"Fang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026022508012338600_ofag046-B35","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus\u2013associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026022508012338600_ofag046-B36","first-page":"102351","article-title":"Escalate: linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial","volume":"142","author":"Sahib","year":"2023","journal-title":"Tuberc Edinb Scotl"},{"key":"2026022508012338600_ofag046-B37","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1093\/infdis\/jiaf089","article-title":"Safety and tolerability of a short course of linezolid for the treatment of predominantly moderate to severe tuberculous meningitis in adults with human immunodeficiency virus","volume":"231","author":"Chow","year":"2025","journal-title":"J Infect Dis"},{"key":"2026022508012338600_ofag046-B38","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1186\/s13063-022-06772-1","article-title":"Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial","volume":"23","author":"Maitre","year":"2022","journal-title":"Trials"},{"key":"2026022508012338600_ofag046-B39"},{"key":"2026022508012338600_ofag046-B40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(25)00213-0","article-title":"Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial","volume":"25","author":"Heinrich","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026022508012338600_ofag046-B41","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1473-3099(25)00289-0","article-title":"Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial","volume":"25","author":"Minja","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026022508012338600_ofag046-B42","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"2026022508012338600_ofag046-B43","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026022508012338600_ofag046-B44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic ClinPharmacol Toxicol"},{"key":"2026022508012338600_ofag046-B45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022508012338600_ofag046-B46","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026022508012338600_ofag046-B47","doi-asserted-by":"crossref","first-page":"106783","DOI":"10.1016\/j.ijantimicag.2023.106783","article-title":"Linezolid monitoring to minimise toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring","volume":"61","author":"Lau","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026022508012338600_ofag046-B48","doi-asserted-by":"crossref","first-page":"e245612","DOI":"10.1136\/bcr-2021-245612","article-title":"Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid","volume":"14","author":"Howell","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2026022508012338600_ofag046-B49","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acsinfecdis.9b00207","article-title":"Radiosynthesis and PET bioimaging of 76Br-bedaquiline in a murine model of tuberculosis","volume":"5","author":"Ordonez","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2026022508012338600_ofag046-B50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-024-01363-6","article-title":"Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling","volume":"63","author":"Mehta","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026022508012338600_ofag046-B51","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1039\/C8RA00984H","article-title":"Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system","volume":"8","author":"Pamreddy","year":"2018","journal-title":"RSC Adv"},{"key":"2026022508012338600_ofag046-B52","doi-asserted-by":"crossref","first-page":"e00913","DOI":"10.1128\/AAC.00913-19","article-title":"Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans","volume":"63","author":"Tucker","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022508012338600_ofag046-B53","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1038\/s41467-024-50989-4","article-title":"Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"2026022508012338600_ofag046-B54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijtb.2024.09.004","article-title":"Drug resistant tuberculous meningitis: a neglected foe in ending tuberculosis epidemic","volume":"72","author":"Inbaraj","year":"2024","journal-title":"Indian J Tuberc"},{"key":"2026022508012338600_ofag046-B55","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1473-3099(24)00223-8","article-title":"Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial","volume":"24","author":"Cevik","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026022508012338600_ofag046-B56","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4269\/ajtmh.1974.23.1116","article-title":"Tissue concentrations of clofazimine (B663) in man","volume":"23","author":"Mansfield","year":"1974","journal-title":"Am J Trop Med Hyg"},{"key":"2026022508012338600_ofag046-B57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijantimicag.2017.08.020","article-title":"Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model","volume":"51","author":"Baijnath","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2026022508012338600_ofag046-B58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10735-015-9634-3","article-title":"Evidence for the presence of clofazimine and its distribution in the healthy mouse brain","volume":"46","author":"Baijnath","year":"2015","journal-title":"J Mol Histol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/2\/ofag046\/67020151\/ofag046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/2\/ofag046\/67020151\/ofag046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:01:32Z","timestamp":1772024492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag046\/8493042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag046","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"ofag046"}}